



No. at Risk								
Rivoceranib	80	62	45	28	15	8	5	0
VEGFRi-naïve	66	51	37	25	13	8	5	0
VEGFRi-treated	14	11	8	3	2	0		

Figure S4. Kaplan-Meier estimate of progression-free survival by blinded independent review committee in the intention-to-treat population. Progression-free survival assessed by blinded independent review committee by prior VEGFR inhibitor treatment.